← Back to patent-cliff list
CAS 272439-95-9
(1S,2S,13S)-2,13-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-12,15,15-trimethyltricyclo[9.3.1.0(3,8)]pentadeca-3,5,7,11-tetraen-9-one
Codes：(LVII)101438-35-e
Application context (from source-drug indications)
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylatePaclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1-[bis(benzyloxy)methyl]-2-bromobenzene→(1S,5E)-1-[(S)-{2-[bis(benzyloxy)methyl]phenyl}(hydroxy)methyl]-4,6,6-trimethyl-5-[(phenylsulfanyl)methylidene]-3-{[tris(propan-2-yl)silyl]oxy}cyclohex-3-en-1-ol→{[(4S,5S,9E)-4-{2-[bis(benzyloxy)methyl]phenyl}-2,8,10,10-tetramethyl-9-[(phenylsulfanyl)methylidene]-1,3-dioxa-2-boraspiro[4.5]dec-7-en-7-yl]oxy}triisopropylsilane→(1S,5S,12R,13R)-12-(benzyloxy)-3,15,18,18-tetramethyl-13-(phenylsulfanyl)-2,4-dioxa-3-boratetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6,8,10,14-tetraen-16-one→(1S,2S,9R,10R)-9-(benzyloxy)-1,2-dihydroxy-12,15,15-trimethyl-10-(phenylsulfanyl)tricyclo[9.3.1.0(3,8)]pentadeca-3,5,7,11-tetraen-13-one→(1S,2S,13S)-13-[(tert-butyldimethylsilyl)oxy]-1,2-dihydroxy-12,15,15-trimethyltricyclo[9.3.1.0(3,8)]pentadeca-3,7,11-trien-9-one→(1S,2S,9R,10R,13S)-9-(benzyloxy)-2,13-bis[(tert-butyldimethylsilyl)oxy]-12,15,15-trimethyl-10-(phenylsulfanyl)tricyclo[9.3.1.0(3,8)]pentadeca-3,5,7,11-tetraen-1-ol→(1S,2S,9S,13S)-9-(benzyloxy)-2,13-bis[(tert-butyldimethylsilyl)oxy]-12,15,15-trimethyltricyclo[9.3.1.0(3,8)]pentadeca-3,5,7,11-tetraen-1-ol→(1S,2S,13S)-2,13-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-12,15,15-trimethyltricyclo[9.3.1.0(3,8)]pentadeca-3,5,7,11-tetraen-9-one→(1S,2S,13S)-2,13-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-12,15,15-trimethyltricyclo[9.3.1.0(3,8)]pentadeca-3,7,11-trien-9-one→(1S,5S,16S)-3,3-di-tert-butyl-16-[(tert-butyldimethylsilyl)oxy]-15,18,18-trimethyl-2,4-dioxa-3-silatetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6,10,14-trien-12-one→(1S,5S,12S,16S)-3,3-di-tert-butyl-16-[(tert-butyldimethylsilyl)oxy]-15,18,18-trimethyl-2,4-dioxa-3-silatetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6,10,14-trien-12-ol→(1S,5Z)-1-hydroxy-4,6,6-trimethyl-5-[(phenylsulfanyl)methylidene]-3-{[tris(propan-2-yl)silyl]oxy}cyclohex-3-ene-1-carbaldehyde→(1S,5S,7R,10S,12S,16S)-3,3-di-tert-butyl-16-[(tert-butyldimethylsilyl)oxy]-15,18,18-trimethyl-2,4-dioxa-3-silatetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-6(11),14-diene-7,10,12-triol
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.